Safety and immunogenicity of a varicella vaccine without human serum albumin (HSA) versus a HSA-containing formulation administered in the second year of life: a phase III, double-blind, randomized study

BACKGROUND: A new formulation of the live-attenuated varicella vaccine Varilrix (GSK) produced without human serum albumin (HSA) was developed to minimize a theoretical risk of transmission of infectious diseases. A previous study showed that the vaccine was immunologically non-inferior to the HSA-c...

Descripción completa

Detalles Bibliográficos
Autores principales: Faust, Saul N., Le Roy, Maguelone, Pancharoen, Chitsanu, Weber, Miguel Angel Rodriguez, Cathie, Katrina, Behre, Ulrich, Bernatoniene, Jolanta, Snape, Matthew D., Helm, Klaus, Medina Pech, Carlos Eduardo, Henry, Ouzama, Baccarini, Carmen, Povey, Michael, Gillard, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366055/
https://www.ncbi.nlm.nih.gov/pubmed/30732648
http://dx.doi.org/10.1186/s12887-019-1425-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366055/
https://www.ncbi.nlm.nih.gov/pubmed/30732648
http://dx.doi.org/10.1186/s12887-019-1425-7

Ejemplares similares